Hi Kara,
Use multi-tissue block controls with normal tissues that are treated
exactly the same (pre-analytically speaking) as your routine surgical
specimens. Consult NordiQC.org for recommended normal control tissue for
each IHC marker. The most used multi-tissue control block in my lab has
Hi martha,
Prognostic markers must be re-validated (Eg.s Breast markers and CD117) as
you described.
Every Ab in your menu should be tested (as you would for a new a new lot)
and do not forget to validate your H (with various tissue types) and SS
as well. For the H, if possible do side-by-side
Kristy:
When validating an IHC procedure, regulatory guidelines like CLIA are not
concerned so much with the types of specimens upon which the procedure will be
applied as they are with how appropriately a given procedure detects different
levels of protein expression, which, in turn, usually
, this should be CAP compliant.
Cae Aguilar, HTL (ASCP)
Histology Supervisor
7079802801
-Original Message-
From: Allan Wang [mailto:all...@biomax.us]
Sent: Thursday, March 22, 2018 11:02 AM
Cc: histonet@lists.utsouthwestern.edu
Subject: Re: [Histonet] IHC validation
How are labs validating for rarer
How are labs validating for rarer biomarkers like ALK, ROS1, or MMR loss?
Following the guideline of 10 positive cases may be difficult.
I've seen other companies with control slides just with a few engineered
cell lines as positive and negative controls. Is that enough for validation
alone?
We
-Original Message-
From: Dessoye, Michael via Histonet [mailto:histonet@lists.utsouthwestern.edu]
Sent: Thursday, March 22, 2018 9:00 AM
To: Terri Braud; 'histonet@lists.utsouthwestern.edu'
Subject: Re: [Histonet] IHC validation
Can anyone recommend a vendor that they've had good luck
-1432 | Fax:
570-552-1484
-Original Message-
From: Terri Braud [mailto:tbr...@holyredeemer.com]
Sent: Tuesday, March 20, 2018 1:54 PM
To: 'histonet@lists.utsouthwestern.edu'
Subject: Re: [Histonet] IHC validation
Just another note: You can order unstained tissue microarrays
-Original Message-
From: Terri Braud [mailto:tbr...@holyredeemer.com]
Sent: Wednesday, 21 March 2018 4:54 AM
To: 'histonet@lists.utsouthwestern.edu' <histonet@lists.utsouthwestern.edu>
Subject: Re: [Histonet] IHC validation
Just another note: You can order unstained tissue micro
I agree Terry,
The TMA slide is a very economical and powerful way to validate with
minimal slides needed.
Colleen Forster
On Tue, Mar 20, 2018 at 12:54 PM, Terri Braud via Histonet <
histonet@lists.utsouthwestern.edu> wrote:
> Just another note: You can order unstained tissue microarrays
Just another note: You can order unstained tissue microarrays with the
prerequisite number of cases, both positive and negative, and stain your
validation all on one slide. I've done this for years and for 3 different
validations of entire IHC platform changes, ranging from 40 to over 100
Hi Dawn,
I would suggest having a look at this CAP guidance paper, below. If I can be
of any assistance, please feel free to contact me.
1. Patrick, L. F. et al. Principles of analytic validation of
immunohistochemical assays: Guideline from the College of American Pathologists
Pathology
I think your last question says it all; it ultimately is up to the director
although she/he better be able to explain to a CAP inspector why it was done
the way it was done. We generally follow the CAP guidelines with 10 - 20
+/10-20 - cases. We've also used the internal negative elements as
; histonet@lists.utsouthwestern.edu
Subject: RE: [Histonet] IHC Validation:
Yes, ultimately up to lab director/medical director/pathologist as to
determination of specificity, selectivity, and if you have enough examples, and
the staining reactivity conforms to the intended clinical use during
Yes, ultimately up to lab director/medical director/pathologist as to
determination of specificity, selectivity, and if you have enough examples, and
the staining reactivity conforms to the intended clinical use during their
assessment and hopefully approval of your protocol. I have used some
All you would need to do is id the tissue and dx on your paperwork. it should
not be any different than running each blocks alone.
susan T. paturzo
TJU
___
Histonet mailing list
Histonet@lists.utsouthwestern.edu
Many labs have turned to tissue microarrays (TMAs) for validating antibodies
for IHC testing as a matter of convenience and lower cost. Ideally, the
tissues used to make the TMA(s) should be fixed in the formalin that is used in
your laboratory, as well as processed in your Histology
Please share to me as well.thanks..
On Mar 27, 2014, at 5:06 PM, Cartun, Richard richard.car...@hhchealth.org
wrote:
I keep an Excel spreadsheet on all my antibodies (and probes). I list the
case number, the tissue tested, the result, is this the expected result?,
diagnosis and/or
I keep an Excel spreadsheet on all my antibodies (and probes). I list the case
number, the tissue tested, the result, is this the expected result?,
diagnosis and/or comments, and the detection system used. I am a firm believer
of maintaining a prospective validation meaning I add positive and
Hi Laurie,
Ideally, you would like to validate both with tissues processed in your
laboratory (controls and patient tissue). Purchased TMAs are okay, but they
should not be the only thing used.
For the instrument validation, I would definitely use tissue that has been
processed in your lab
Laurie, I would use the control slides to validate and set up the antibodies. I
good secondary check/control would be to send slides to another lab to check
for correlation and confirmation of your protocol performance. Once you get an
established process, then you can later check patient
Hi,
Think of yourself as a reference lab as well. You have a validated
protocol for one clone already. Validate the new clone against the
current. Your medical director can help you determine how many cases are
sufficient. Depending on the antibody we validate anywhere from five
cases to
-Original Message-
From: histonet-boun...@lists.utsouthwestern.edu
[mailto:histonet-boun...@lists.utsouthwestern.edu]On Behalf Of Dessoye,
Michael J
Sent: Friday, May 04, 2012 7:51 AM
To: histonet@lists.utsouthwestern.edu
Subject: [Histonet] IHC Validation
Hello all,
A year or so
Tim
Use outside controls to validate your own internal controls. Normal control
tissue is acceptable and is useful because it has consistent expression of the
antigen. Cancer tissue is quite variable in expression and sometimes the
expected expression is less than the normal tissue, and
Not really because the Hematoxylin should affect only the nuclei UNLESS it is
a nuclear antibody, in which case the antigenic reaction could be obscured.
For nuclear Abs I used to dilute my hematoxylin as much as possible or did not
use it at all.
René J.
--- On Tue, 4/19/11, Ring, Mary L
In my opinion, only if it affects immunoreactivity.
Richard
Richard W. Cartun, MS, PhD
Director, Histology Immunopathology
Director, Biospecimen Collection Programs
Assistant Director, Anatomic Pathology
Hartford Hospital
80 Seymour Street
Hartford, CT 06102
(860) 545-1596 Office
(860)
Subject
02/09/2011 03:26 Re: [Histonet] IHC validation
PM
...@sjha.org
Subject: RE: [Histonet] IHC validation
To: Liz Chlipala l...@premierlab.com, Joe Nocito
jnoc...@satx.rr.com, Histonet histonet@lists.utsouthwestern.edu
Message-ID:
92ad9b20a6c38c4587a9febe3a30e164081e09a...@chexcms10.one.ads.che.org
Content-Type: text/plain; charset=us
Joe:
This is what I would do;
1- run 1 control slide per antibody you have in your arsenal
2- compare the result with a control slide already in your files.
3- show both slides to the chief pathologist (after all is his/her opinion the
one is going to be asked by CAP)
4- those antibodies whose
...@lists.utsouthwestern.edu
[mailto:histonet-boun...@lists.utsouthwestern.edu] On Behalf Of Rene J Buesa
Sent: Wednesday, February 09, 2011 3:27 PM
To: Histonet; Joe Nocito
Subject: Re: [Histonet] IHC validation
Joe:
This is what I would do;
1- run 1 control slide per antibody you have in your arsenal
2- compare
Joe
If you are following the recommendations from the CAP paper on IHC
standardization then it would be 25 tissues (10 strong positive, 10 weak
to moderate positive and 5 negative).
Liz
Elizabeth A. Chlipala, BS, HTL(ASCP)QIHC
Manager
Premier Laboratory, LLC
PO Box 18592
Boulder, Colorado
Subject: RE: [Histonet] IHC validation
Joe
If you are following the recommendations from the CAP paper on IHC
standardization then it would be 25 tissues (10 strong positive, 10 weak to
moderate positive and 5 negative).
Liz
Elizabeth A. Chlipala, BS, HTL(ASCP)QIHC Manager Premier Laboratory
Chlipala; Joe Nocito; Histonet
Subject: RE: [Histonet] IHC validation
But that is for receptors, correct? Do you do that for everything?
Thanks, j
-Original Message-
From: histonet-boun...@lists.utsouthwestern.edu
[mailto:histonet-boun...@lists.utsouthwestern.edu] On Behalf Of Liz
Chlipala
Nocito; Histonet
Subject: RE: [Histonet] IHC validation
Nope that's the recommendation for everything, in the paper they state
additional development is required for prognostic markers. Once you have
validated an antibody it only requires 3 tissues when you get a new lot
number: 1 strong positive
...@ucsfmedctr.org]
Sent: Tuesday, February 08, 2011 4:38 PM
To: Liz Chlipala; Weems, Joyce; Joe Nocito; Histonet
Subject: RE: [Histonet] IHC validation
When changing instruments you are validating the instrument, not the
test. For each antibody you just need to run parallel tests in each
instrument showing
Chlipala' l...@premierlab.com; Weems, Joyce jwe...@sjha.org;
Joe Nocito jnoc...@satx.rr.com; Histonet
histonet@lists.utsouthwestern.edu
Sent: Tuesday, February 08, 2011 5:37 PM
Subject: RE: [Histonet] IHC validation
When changing instruments you are validating the instrument, not the test.
For each
Liz:
I'd like to know more about these recommendations. Could you provide a
journal reference to the paper from CAP?
Thx,
Sally
--
Message: 15
Date: Tue, 8 Feb 2011 16:19:53 -0700
From: Liz Chlipala l...@premierlab.com
Subject: RE: [Histonet] IHC validation
To: Weems
We perform our entire validation process as a new piece of equipment.
Our validation protocols are quite extensive, up to about 85 pages long
on each piece of major equipment, at least that's what it was for our
new prisma stainer and glass coverslipper. We perform an
installation/operational
Laurie
I'm not aware of a particular question, but I would believe you would
have to perform some validation steps for each antibody. I would
approach it the same way you approach validating new lots of antisera.
The CAP paper on standardization of IHC recommends 25 different samples
when you
38 matches
Mail list logo
